Introduction
Over the past 2 years, the results of large clinical trials have fundamentally changed the clinical practice of stroke care in several different ways. Perhaps the greatest advances have occurred in stroke prevention, where we now have a wider array of anticoagulants to reduce the risk of stroke in patients with atrial fibrillation and we have confirmation from 2 large studies that medical therapies are more effective at stroke prevention than endovascular and surgical procedures for patients with intracranial atherosclerotic disease and internal carotid occlusion, respectively. However, new technological improvements have advanced endovascular techniques for acute ischemic stroke (AIS) to the point where we are on the verge of determining whether intra-arterial treatments may actually improve outcome. We discuss the highlights of several important articles during the past 2 years that have advanced the field in emerging therapies for stroke.
Acute Ischemic Stroke
Although no major advances have yet led to the approval of novel thrombolytic agents for AIS, the long awaited placebo-controlled IST-3 trial on IV t-PA for AIS was finally completed. IST-3 is the largest thrombolysis trial ever involving >3000 patients, confirming once again the benefits of IV t-PA and that, in unselected patients, alteplase is most effective in the 3-hour time window.1 The study supports the long-held notion that selected criteria are needed to identify patients who would benefit in time windows beyond 3 hours from symptom onset. In this respect, Parson et al,2 conducted a phase IIB trial in which alteplase was compared with tenecteplase in patients who had a large artery occlusion and a perfusion lesion at least 20% greater than the infarct core on computed tomographic perfusion. Tenecteplase was associated with better reperfusion and better clinical outcomes compared with alteplase.2 …
Jump to
This Issue
Article Tools
Share this Article
- Advances in StrokePermalink:
